ReviewWorld journal of gastrointestinal oncology2018
Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data.
Review in World journal of gastrointestinal oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.JNCI cancer spectrum · 2024Pooled it
- The prognostic impact of human epidermal growth factor receptor 2 status in metastatic colorectal cancer.Future science OA · 2025Article
- Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Narrative review of neoadjuvant therapy in patients with locally advanced colon cancer.The Kaohsiung journal of medical sciences · 2025Review
- An Updated Review on Molecular Biomarkers in Diagnosis and Therapy of Colorectal Cancer.Current cancer drug targets · 2024Review
- Review
- Networks as Biomarkers: Uses and Purposes.Genes · 2023Review
- FSP-1 expression in cancer cells is relevant to long-term oncological outcomes in nonmetastatic colorectal cancer.Korean journal of clinical oncology · 2022Article
- Review
- Article
- The Utility of Serum Vasorin Levels as a Novel Potential Biomarker for Early Detection of Colon Cancer.Cureus · 2022Article
- HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer.Cell death & disease · 2021Article
- GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.Expert review of precision medicine and drug development · 2021Article
- Identification of Whole-Serum Glycobiomarkers for Colorectal Carcinoma Using Reverse-Phase Lectin Microarray.Frontiers in oncology · 2021Article
- IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma.Molecular biology reports · 2020Article
- Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications.Advanced functional materials · 2020Article
- Novel biomarkers for the diagnosis and prognosis of colorectal cancer.Intestinal research · 2020Review
- Gut butyrate-producing organisms correlate to Placenta Specific 8 protein: Importance to colorectal cancer progression.Journal of advanced research · 2020Article
- Biomarkers for Stratification in Colorectal Cancer: MicroRNAs.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Colorectal cancer (CRC) treatment has become more personalised, incorporating a combination of the individual patient risk assessment, gene testing, and chemotherapy with surgery for optimal care. The improvement of staging with high-resolution imaging has allowed more selective treatments, optimising survival outcomes. The next step is to identify biomarkers that can inform clinicians of expected prognosis and offer the most beneficial treatment, while reducing unnecessary morbidity for the patient. The search for biomarkers in CRC has been of significant interest, with questions remaining on their impact and applicability. The study of biomarkers can be broadly divided into metabolic, molecular, microRNA, epithelial-to-mesenchymal-transition (EMT), and imaging classes. Although numerous molecules have claimed to impact prognosis and treatment, their clinical application has been limited. Furthermore, routine testing of prognostic markers with no demonstrable influence on response to treatment is a questionable practice, as it increases cost and can adversely affect expectations of treatment. In this review we focus on recent developments and emerging biomarkers with potential utility for clinical translation in CRC. We examine and critically appraise novel imaging and molecular-based approaches; evaluate the promising array of microRNAs, analyze metabolic profiles, and highlight key findings for biomarker potential in the EMT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.